Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements. "We are...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4th at 11:30 a.m. Eastern Time to...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from...
Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences: Stifel 2022 Virtual...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the publication of positive Phase 2 data for...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program,...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a panel discussion on orphan neurological disease...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent...
CARLSBAD, Calif., Feb. 10, 2022 /PRNewswire/ – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on...
Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA)...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced two appointments that strengthen its leadership team and further position it to become a...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at...
Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the closing of the collaboration agreement with...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a virtual investor day on Thursday, December 9th at 11:00 a.m. Eastern...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE, the registrational study...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the upcoming presentations of clinical and...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following virtual...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.